July 2, 2024
BURLINGTON, Ontario – July 2, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), the Company intends to issue common shares...
July 2, 2024
Burlington, Ontario – June 28, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), is pleased to announce the filing of its financial results for the year ended February 29, 2024. Mark Upsdell, Chairman and Chief Executive Officer, stated, “Over the past...
June 25, 2024
Burlington, Ontario – June 25, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) trading on the Canadian Securities Exchange (“CSE”) under the symbol DOSE is pleased to announce the recent award of a Mitacs Accelerate grant, with a value of $30,000 in May...
June 19, 2024
BURLINGTON, Ontario – June 17, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated May 8, 2024, regarding a proposed equity private placement financing (the “Financing”), the Company has received an extension from...
May 29, 2024
BURLINGTON, Ontario – May 29, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces its collaboration in the National Football League (NFL) – funded clinical trial program entitled “Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in...
May 22, 2024
Burlington, Ontario – May 22, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) trading on the Canadian Securities Exchange (“CSE”) under the symbol DOSE in partnership with McMaster University (“McMaster”) is pleased to announce the publication of the results of their collaborative research...
May 16, 2024
BURLINGTON, Ontario – May 16, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $250,000 in a fifth tranche of its previously announced private placement financing (the “Financing”), bringing the total amount raised to $1,960,000. ...
May 9, 2024
BURLINGTON, Ontario – May 8, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated March 25, 2024, announcing a proposed equity private placement financing (the “Financing”), the Company has received an extension from...
April 16, 2024
BURLINGTON, Ontario – April 15, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $300,000 in a fourth tranche of its previously announced equity private placement financing (the “Financing”), bringing the total amount raised to...
April 3, 2024
BURLINGTON, Ontario – April 3, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $110,000 in a third tranche of its previously announced equity private placement financing (the “Financing”), bringing the total amount raised to...